Insmed Incorporated (INSM)
NASDAQ: INSM · IEX Real-Time Price · USD
24.80
-0.12 (-0.48%)
At close: Apr 26, 2024, 4:00 PM
24.50
-0.30 (-1.21%)
After-hours: Apr 26, 2024, 7:55 PM EDT
Insmed Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Insmed stock have an average target of 45.58, with a low estimate of 36 and a high estimate of 55. The average target predicts an increase of 83.79% from the current stock price of 24.80.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Insmed stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 5 |
| Buy | 6 | 6 | 6 | 5 | 5 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 9 | 9 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $48 | Strong Buy | Initiates | $48 | +93.55% | Apr 23, 2024 |
| Barclays | Barclays | Buy Maintains $37 → $40 | Buy | Maintains | $37 → $40 | +61.29% | Apr 11, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $55 | Buy | Maintains | $55 | +121.77% | Apr 1, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $52 → $54 | Strong Buy | Maintains | $52 → $54 | +117.74% | Feb 27, 2024 |
| UBS | UBS | Strong Buy Initiates $46 | Strong Buy | Initiates | $46 | +85.48% | Feb 27, 2024 |
Financial Forecast
Revenue This Year
363.12M
from 305.21M
Increased by 18.97%
Revenue Next Year
526.78M
from 363.12M
Increased by 45.07%
EPS This Year
-4.69
from -5.34
EPS Next Year
-3.88
from -4.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 396.1M | 645.8M | 1.3B | 1.7B | 2.8B |
| Avg | 363.1M | 526.8M | 852.0M | 1.2B | 1.7B |
| Low | 336.8M | 414.5M | 570.4M | 732.2M | 885.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.8% | 77.8% | 143.0% | 98.9% | 121.6% |
| Avg | 19.0% | 45.1% | 61.7% | 46.1% | 39.1% |
| Low | 10.4% | 14.2% | 8.3% | -14.1% | -28.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.90 | -3.01 | -1.53 | 0.82 | 3.14 |
| Avg | -4.69 | -3.88 | -2.35 | -0.36 | 1.31 |
| Low | -5.15 | -5.46 | -3.49 | -2.90 | -1.35 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.